The FDA slammed ExThera with a warning letter for deviating from the regulatory agency’s guidelines by promoting and selling ...

BioNTech and partner DualityBio are accelerating the development of their B7-H3 antibody-drug conjugate into a phase 3 trial for metastatic castration-resistant prostate cancer (mCRPC). | BioNTech and ...

On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. | On some level, Eli Lilly’s partnership with computing giant Nvidia feels inevitable. The first pharma to reach a ...

Most immuno-oncology drugs work by altering the tumor microenviro | This webinar covers how recent advances in multiplex ...

A new biotech has taken flight as a result of Novartis’ red-hot $12 billion acquisition of muscular dystrophy specialist Avidity Biosciences. | A new biotech has risen from the ashes of Novartis’ ...

Thermo Fisher Scientific is launching a new test it says can help doctors avoid the “trial-and-error” approach typically used ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. | A “fairly shocking and certainly ironic twist of fate” is ending ...

A panel of physicians, biotech leaders and patient advocates took aim at the FDA during a Senate hearing Thursday on how the ...

A Chinese phase 3 trial of Bristol Myers Squibb’s antibody-drug conjugate has hit its dual primary survival endpoints, ...

Following the launch of its Wegovy (semaglutide) pill at the beginning of the year, Novo Nordisk is committing as much as ...

Asahi Kasei has unveiled plans to acquire Aicuris in a deal worth 780 million euros ($920 million), marking the latest in a ...

Artificial intelligence research biotech Earendil Labs has penned an $885 million deal to use WuXi XDC’s linker-payload technology to create next-gen antibody-drug conjugates. | AI research biotech ...